StocksFundsScreenerSectorsWatchlists
BAX

BAX - Baxter International Inc Stock Price, Fair Value and News

39.48USD-0.17 (-0.43%)Market Closed

Market Summary

BAX
USD39.48-0.17
Market Closed
-0.43%

BAX Stock Price

View Fullscreen

BAX RSI Chart

BAX Valuation

Market Cap

20.0B

Price/Earnings (Trailing)

7.55

Price/Sales (Trailing)

1.35

EV/EBITDA

37.51

Price/Free Cashflow

11.62

BAX Price/Sales (Trailing)

BAX Profitability

EBT Margin

-0.51%

Return on Equity

31.61%

Return on Assets

9.39%

Free Cashflow Yield

8.61%

BAX Fundamentals

BAX Revenue

Revenue (TTM)

14.8B

Rev. Growth (Yr)

3.74%

Rev. Growth (Qtr)

4.77%

BAX Earnings

Earnings (TTM)

2.7B

Earnings Growth (Yr)

35.36%

Earnings Growth (Qtr)

-90.23%

Breaking Down BAX Revenue

Last 7 days

-2.1%

Last 30 days

-5.6%

Last 90 days

2.3%

Trailing 12 Months

-8.7%

How does BAX drawdown profile look like?

BAX Financial Health

Current Ratio

1.48

Debt/Equity

1.32

Debt/Cashflow

0.16

BAX Investor Care

Dividend Yield

1.63%

Dividend/Share (TTM)

0.67

Shares Dilution (1Y)

0.63%

Diluted EPS (TTM)

5.22

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202314.5B14.6B14.7B14.8B
202212.8B13.3B13.6B14.5B
202111.8B12.2B12.5B12.1B
202011.5B11.4B11.5B11.7B
201911.0B11.1B11.2B11.4B
201810.8B11.0B11.0B11.1B
201710.3B10.3B10.4B10.6B
20169.9B10.1B10.1B10.2B
201510.6B10.4B10.2B10.0B
201414.1B13.3B12.3B10.7B
201314.2B14.2B14.4B15.0B
201214.0B14.0B14.0B14.2B
201113.2B13.5B13.8B13.9B
201012.7B12.7B12.8B12.8B
200912.3B12.2B12.2B12.6B
2008011.6B12.0B12.3B
200700011.3B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Baxter International Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 06, 2024
rosenbloom david s.
acquired
-
-
53,584
evp and general counsel
Mar 06, 2024
borzi james w
acquired
-
-
33,341
evp,chief supply chain officer
Mar 06, 2024
almeida jose e
acquired
-
-
142,891
chairman, ceo, president
Mar 06, 2024
knight heather
acquired
-
-
107,168
evp,group pres,med products
Mar 06, 2024
toth christopher a.
acquired
-
-
119,076
evp,group pres, kidney care
Mar 06, 2024
grade joel t.
acquired
-
-
42,867
evp and cfo
Mar 06, 2024
rasul reazur
acquired
-
-
83,353
evp,group pres, healthcare
Mar 06, 2024
stevens brian
acquired
-
-
14,289
svp, cao & controller
Mar 06, 2024
mason jeanne k
acquired
-
-
47,630
evp, chief hr officer
Mar 06, 2024
sonig alok
acquired
-
-
83,353
evp,group president, pharma

1–10 of 50

Which funds bought or sold BAX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 18, 2024
Park Place Capital Corp
unchanged
-
2,624
27,482
0.01%
Apr 18, 2024
MV CAPITAL MANAGEMENT, INC.
added
0.84
11,659
113,219
0.01%
Apr 18, 2024
FARMERS & MERCHANTS INVESTMENTS INC
unchanged
-
34,068
356,879
0.01%
Apr 18, 2024
PLIMOTH TRUST CO LLC
new
-
201,390
201,390
0.05%
Apr 18, 2024
MEAG MUNICH ERGO, Kapitalanlagegesellschaft mbH
sold off
-100
-270,620
-
-%
Apr 18, 2024
West Oak Capital, LLC
unchanged
-
2,000
36,000
0.01%
Apr 18, 2024
McGlone Suttner Wealth Management, Inc.
sold off
-100
-382
-
-%
Apr 18, 2024
SILVERLAKE WEALTH MANAGEMENT LLC
new
-
477,278
477,278
0.24%
Apr 18, 2024
Piscataqua Savings Bank
added
3.06
4,578
37,430
0.03%
Apr 18, 2024
STATE OF MICHIGAN RETIREMENT SYSTEM
added
0.14
575,375
5,946,330
0.03%

1–10 of 50

Are Funds Buying or Selling BAX?

Are funds buying BAX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BAX
No. of Funds

Unveiling Baxter International Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
dodge & cox
5.4%
27,381,465
SC 13G
Feb 13, 2024
vanguard group inc
11.86%
60,155,132
SC 13G/A
Jan 23, 2024
blackrock inc.
11.8%
59,678,841
SC 13G/A
May 09, 2023
morgan stanley
0.6%
3,186,104
SC 13G/A
Apr 10, 2023
wellington management group llp
0.11%
559,390
SC 13G/A
Apr 10, 2023
vanguard group inc
12.03%
60,794,820
SC 13G/A
Feb 09, 2023
vanguard group inc
9.86%
49,705,350
SC 13G/A
Feb 08, 2023
morgan stanley
5.5%
27,835,167
SC 13G/A
Feb 06, 2023
wellington management group llp
7.16%
36,104,233
SC 13G/A
Jan 06, 2023
blackrock inc.
10.0%
50,522,292
SC 13G/A

Recent SEC filings of Baxter International Inc

View All Filings
Date Filed Form Type Document
Mar 27, 2024
DEFA14A
DEFA14A
Mar 25, 2024
DEF 14A
DEF 14A
Mar 25, 2024
DEFA14A
DEFA14A
Mar 21, 2024
8-K
Current Report
Mar 14, 2024
PRE 14A
PRE 14A
Mar 08, 2024
4
Insider Trading
Mar 08, 2024
4
Insider Trading
Mar 08, 2024
4
Insider Trading
Mar 08, 2024
4
Insider Trading
Mar 08, 2024
4
Insider Trading

Peers (Alternatives to Baxter International Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
186.2B
40.1B
-3.77% -2.76%
32.53
4.64
-8.12% -17.45%
67.7B
19.5B
-1.53% -10.57%
53.87
3.47
4.02% -22.04%
22.5B
3.9B
-9.16% -15.16%
50.45
5.81
3.42% 23.09%
20.0B
14.8B
-5.62% -8.72%
7.55
1.35
2.12% 209.17%
MID-CAP
9.2B
3.5B
-0.49% 17.01%
32.32
2.64
4.97% 18.89%
9.1B
12.3B
-5.22% -14.61%
21.9
0.74
-2.44% -22.68%
8.2B
2.7B
-16.90% -39.13%
-12.81
3.06
-4.68% 82.43%
6.3B
4.0B
-8.41% -25.34%
-47.02
1.6
1.10% 85.84%
3.4B
366.4M
-2.66% 12.41%
-562.39
9.32
33.86% 89.83%
2.3B
6.6B
-4.93% -3.92%
12.04
0.35
2.78% -0.87%
SMALL-CAP
1.2B
3.2B
-14.38% -20.49%
-1.83
0.39
7.73% -1066.14%
383.3M
166.7M
0.86% -5.21%
-4.64
2.3
6.67% -456.34%
250.3M
324.0M
11.81% -29.38%
-1.3
0.77
-3.19% -337.41%
45.7M
52.3M
-28.65% -55.25%
-2.44
0.87
17.61% 19.28%
3.8M
3.7M
-10.98% 147.46%
-0.31
1.02
5.77% 8.23%

Baxter International Inc News

Latest updates
MarketWatch25 hours ago
MarketBeat16 Apr 202411:51 am
Yahoo Finance13 Mar 202407:00 am
Seeking Alpha26 Feb 202408:00 am
Yahoo Finance2 months ago

Baxter International Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue4.8%3,8853,7083,7073,5133,7453,6093,5943,5582,8763,2263,0982,9463,1812,9722,7182,8023,0392,8512,8342,6382,833
Gross Profit31.8%1,4721,1171,1111,2751,3881,0451,3711,2621,0211,3211,2331,1451,1911,1951,0381,1631,2981,2301,1531,0801,183
  S&GA Expenses-2.4%9781,0029641,0108999419701,052863680675627650601590628666627641601627
  R&D Expenses3.6%172166165164154151148150135129139128135123117146156144166129175
EBITDA Margin20.0%0.05*0.04*-0.13*-0.10*-0.09*-0.10*0.14*0.15*0.17*0.17*0.17*0.17*---------
Interest Expenses43.0%-73.00-128-124-117-117-104-89.00-85.00-75.00-50.00-34.00-34.00-38.00-39.00-36.00-21.00-20.00-13.00-20.00-18.00-11.00
Income Taxes171.5%160-22310.0025.0011.00-54.0034.0021.00-58.00-1.0091.0051.0039.0056.0042.0045.00-20410613.0044.00102
Earnings Before Taxes222.1%210-172-18370.00122-3,04521994.00-78.00451392351210415289378-223481326386413
EBT Margin54.4%-0.01*-0.01*-0.19*-0.16*-0.16*-0.17*0.07*0.09*0.12*0.11*0.11*0.11*---------
Net Income-90.2%2452,508-14144.00181-2,93725271.00238450298298168356246332-23.00369313342305
Net Income Margin1.5%0.18*0.18*-0.19*-0.17*-0.17*-0.16*0.07*0.08*0.10*0.10*0.09*0.09*---------
Free Cashflow45.5%531365351479439290274208693675477377---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-7.8%28,27630,65627,88528,29128,28727,96531,83132,71633,52119,80719,68219,46620,01920,09819,46519,07518,19317,29917,50316,24115,720
  Current Assets-20.2%9,60012,0348,2058,0998,0117,8107,8828,1738,8728,1678,0047,8568,4119,0338,5668,3337,5037,2107,2296,0605,959
    Cash Equivalents-44.8%3,1945,7881,7221,6731,7181,6011,8522,2942,9513,2583,1363,1823,7364,3594,0854,1103,3353,0092,9341,9021,838
  Inventory-1.7%2,8242,8732,8972,9222,6792,6752,6632,5482,4532,0252,0652,0171,9161,9881,9051,6941,6531,7151,7561,7431,667
  Net PPE3.6%4,4334,2784,4945,0004,6954,7994,9765,1145,1784,5824,6494,6144,7224,4604,3824,3404,5124,4064,4854,4764,530
  Goodwill1.7%6,5146,4076,4186,8686,4526,6399,6449,8169,4183,0983,1481.003,2173,0943,0522,9613,0302,8472,937--
Liabilities-11.9%19,80822,49022,25422,35022,39222,38622,92823,59724,40010,99211,14710,97611,29311,49611,30511,34510,2819,6829,7008,6487,854
  Current Liabilities4.7%6,5036,2095,7654,7604,7453,7083,9163,8904,2363,4413,3443,1873,3333,4222,8803,0363,2302,6112,5573,2762,814
  Short Term Borrowings-100.0%-51424950.0029927520020030130151.00---1.00221226-2.007962.00
  Long Term Debt-20.9%11,13014,06714,30615,27815,23216,153--17,149-------4,809-5,1573,4513,481
Shareholder's Equity3.7%8,4028,1015,6315,9415,8335,5798,9039,1199,1218,8158,5358,4908,7268,6028,1607,7307,9127,6177,8037,5937,866
  Retained Earnings0.6%16,11416,01513,65513,94714,05014,01517,09916,99417,06516,96716,65816,50216,32816,28516,05515,93515,71815,84915,59815,41415,075
  Additional Paid-In Capital0.3%6,3896,3686,3416,3126,3226,2976,2536,2076,1976,1316,0906,0436,0436,0095,9755,9355,9555,9265,9065,8395,898
Shares Outstanding-0.2%506507506505504503503503502500503505---------
Minority Interest1.5%66.0065.0062.0062.0062.0044.0044.0044.0044.0045.0041.0038.0037.0035.0032.0031.0030.0029.0024.0023.0022.00
Float---23,000---32,000---40,000---44,000---42,000--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations45.5%531365351479439290274208693675477377712510374272829701446128709
  Share Based Compensation-26.8%30.0041.0037.0025.0031.0045.0045.0032.0053.0034.0037.0022.0033.0033.0035.0029.0030.0035.0035.0022.0028.00
Cashflow From Investing-106.1%-2303,786-173-170-256-184-187-304-10,267-207-188-538-264-157-154-604-421-231-147-301-216
Cashflow From Financing-4633.9%-2,935-62.00-120-372-119-302-469-5489,276-324-349-358-1,143-111-2611,170-116-354730238-1,508
  Dividend Payments0%14714714614614614614114014014112412512512511211111311297.00101102
  Buy Backs------32.00---35.00312253500---2413091235971,424

BAX Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF INCOME (LOSS) - USD ($)
shares in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Net sales$ 14,813,000,000$ 14,506,000,000$ 12,146,000,000
Cost of sales9,838,000,0009,440,000,0007,426,000,000
Gross margin4,975,000,0005,066,000,0004,720,000,000
Selling, general and administrative expenses3,946,000,0003,859,000,0002,845,000,000
Research and development expenses667,000,000602,000,000531,000,000
Goodwill impairments02,812,000,0000
Other operating expense (income), net(28,000,000)36,000,000(6,000,000)
Operating income (loss)390,000,000(2,243,000,000)1,350,000,000
Interest expense, net442,000,000395,000,000193,000,000
Other (income) expense, net51,000,00012,000,00041,000,000
Income (loss) from continuing operations before income taxes(103,000,000)(2,650,000,000)1,116,000,000
Income tax (benefit) expense(34,000,000)4,000,00083,000,000
Income (loss) from continuing operations(69,000,000)(2,654,000,000)1,033,000,000
Income from discontinued operations, net of tax2,732,000,000233,000,000262,000,000
Net income (loss)2,663,000,000(2,421,000,000)1,295,000,000
Net income attributable to noncontrolling interests7,000,00012,000,00011,000,000
Net income (loss) attributable to Baxter stockholders$ 2,656,000,000$ (2,433,000,000)$ 1,284,000,000
Income (loss) from continuing operations per common share   
Basic (in dollars per share)$ (0.15)$ (5.29)$ 2.04
Diluted (in dollars per share)(0.15)(5.29)2.01
Income from discontinued operations per common share   
Basic (in dollars per share)5.400.460.52
Diluted (in dollars per share)5.400.460.52
Net Income (loss) per common share   
Basic (in dollars per share)5.25(4.83)2.56
Diluted (in dollars per share)$ 5.25$ (4.83)$ 2.53
Weighted-average number of shares outstanding   
Basic (in shares)506504502
Diluted (in shares)506504508

BAX Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 3,194$ 1,718
Accounts receivable, net of allowance of $129 in 2023 and $114 in 20222,6902,571
Inventories2,8242,679
Prepaid expenses and other current assets892857
Current assets of discontinued operations0186
Total current assets9,6008,011
Property, plant and equipment, net4,4334,695
Goodwill6,5146,452
Other intangible assets6,0796,793
Operating lease right-of-use assets524541
Other non-current assets1,1261,109
Non-current assets of discontinued operations0686
Total assets28,27628,287
Current liabilities:  
Short-term debt0299
Current maturities of long-term debt and finance lease obligations2,6681,105
Accounts payable1,2411,110
Accrued expenses and other current liabilities2,5942,170
Current liabilities of discontinued operations061
Total current liabilities6,5034,745
Long-term debt and finance lease obligations11,13015,232
Operating lease liabilities438447
Other non-current liabilities1,7371,848
Non-current liabilities of discontinued operations0120
Total liabilities19,80822,392
Commitments and contingencies
Equity:  
Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2023 and 2022683683
Common stock in treasury, at cost, 175,861,893 shares in 2023 and 179,062,594 shares in 2022(11,230)(11,389)
Additional contributed capital6,3896,322
Retained earnings16,11414,050
Accumulated other comprehensive income (loss)(3,554)(3,833)
Total Baxter stockholders’ equity8,4025,833
Noncontrolling interests6662
Total equity8,4685,895
Total liabilities and equity$ 28,276$ 28,287
BAX
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules; and a collaborative research agreement with Miromatrix Medical Inc. to develop treatments for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is based in Deerfield, Illinois.
 CEO
 WEBSITEbaxter.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES60000

Baxter International Inc Frequently Asked Questions


What is the ticker symbol for Baxter International Inc? What does BAX stand for in stocks?

BAX is the stock ticker symbol of Baxter International Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Baxter International Inc (BAX)?

As of Fri Apr 19 2024, market cap of Baxter International Inc is 20.05 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BAX stock?

You can check BAX's fair value in chart for subscribers.

What is the fair value of BAX stock?

You can check BAX's fair value in chart for subscribers. The fair value of Baxter International Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Baxter International Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BAX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Baxter International Inc a good stock to buy?

The fair value guage provides a quick view whether BAX is over valued or under valued. Whether Baxter International Inc is cheap or expensive depends on the assumptions which impact Baxter International Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BAX.

What is Baxter International Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, BAX's PE ratio (Price to Earnings) is 7.55 and Price to Sales (PS) ratio is 1.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BAX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Baxter International Inc's stock?

In the past 10 years, Baxter International Inc has provided 0.014 (multiply by 100 for percentage) rate of return.